Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ningbo Menovo Pharmaceutical Co's quarterly Total Liabilities
increased
from Sep. 2025 (¥2,329.04 Mil) to Dec. 2025 (¥2,401.52 Mil) but then
declined
from Dec. 2025 (¥2,401.52 Mil) to Mar. 2026 (¥2,103.86 Mil).
Ningbo Menovo Pharmaceutical Co's annual Total Liabilities
increased
from Dec. 2023 (¥2,237.83 Mil) to Dec. 2024 (¥2,359.78 Mil) and
increased
from Dec. 2024 (¥2,359.78 Mil) to Dec. 2025 (¥2,401.52 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ningbo Menovo Pharmaceutical Co Total Liabilities Chart
Ningbo Menovo Pharmaceutical Co Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ningbo Menovo Pharmaceutical Co (SHSE:603538) has a Total Liabilities of ¥2,104 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ningbo Menovo Pharmaceutical Co and its competitors.
Is Ningbo Menovo Pharmaceutical Co's Total Liabilities too high?
Ningbo Menovo Pharmaceutical Co's current Total Liabilities is ¥2,104 Mil. Overall, Ningbo Menovo Pharmaceutical Co has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Menovo Pharmaceutical Co's Total Liabilities compare to ZTS?
Ningbo Menovo Pharmaceutical Co's Total Liabilities of ¥2,104 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ningbo Menovo Pharmaceutical Co and its competitors. Ningbo Menovo Pharmaceutical Co's current Total Liabilities is ¥2,104 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Menovo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co (SHSE:603538) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥16.40, compared to a current price of ¥24.90 — trading 51.8% above its estimated fair value. The current Total Liabilities is ¥2,104 Mil. Ningbo Menovo Pharmaceutical Co's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Ningbo Menovo Pharmaceutical Co (SHSE:603538), the current Total Liabilities is ¥2,104 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥24.90 is trading 51.8% above its estimated GF Value™ of ¥16.40.
GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:603538:
Total Liabilities: ¥2,104 Mil
GF Value™: ¥16.40 vs. price of ¥24.90 (51.8% above fair value)
No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
64GF Score
Get the complete analysis for SHSE:603538
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603538 has been successfully added to your 
